Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function
Completed · Phase 1
Conditions studied: Hepatic Impairment, Healthy Participants
In brief
The primary objective of this study is to assess the pharmacokinetics (PK) of linzagolix in subjects with varying degrees of impaired hepatic function compared to match control subjects with normal hepatic function
Key facts
- Study ID
- NCT03962049
- Run by
- ObsEva SA
- People needed
- 24
- Starts
- 2019-05-15
- Expected to finish
- 2019-11-01
- Last updated by the study team
- 2020-01-13
Who can join
Age: 18 and older, up to 75. Sex: female. Healthy volunteers: accepted.
Where it is running
- Clinical Site — Hialeah, Florida, United States
- Clinical Site — Orlando, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.